Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Pegvaliase

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6Gowling WLG (Canada) LLP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687028

    Filing Date : 2008-08-15

    Strength per Unit : 2.5mg / 0.5mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687450

    Filing Date : 2008-05-23

    Strength per Unit : 2.5mg / 0.5mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687028

    Filing Date : 2008-08-15

    Strength per Unit : 10mg / 0.5mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687450

    Filing Date : 2008-05-23

    Strength per Unit : 10mg / 0.5mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687028

    Filing Date : 2008-08-15

    Strength per Unit : 20mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-08-15

    Date Granted : 2016-02-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Gowling WLG (Canada) LLP

    PEGVALIASE
    arrow
    ChemOutsourcing
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    PEGVALIASE

    Brand Name : PALYNZIQ

    Patent Number : 2687450

    Filing Date : 2008-05-23

    Strength per Unit : 20mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-05-23

    Date Granted : 2019-03-26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF